Company Description
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer.
The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform that targets claudin 18.2, which is overexpressed in gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types.
The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc.; and license agreement with Stanford University.
The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015.
Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
| Country | United States |
| Founded | 2015 |
| IPO Date | Feb 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 52 |
| CEO | William Quinn |
Contact Details
Address: 900 Chesapeake Drive Redwood City, California 94063 United States | |
| Phone | 650 665 9295 |
| Website | boltbio.com |
Stock Details
| Ticker Symbol | BOLT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001641281 |
| CUSIP Number | 097702104 |
| ISIN Number | US0977021049 |
| Employer ID | 47-2804636 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| William P. Quinn | Chief Executive Officer, Chief Financial Officer, President, Secretary and Director |
| Grant Yonehiro C.F.A., M.B.A. | Chief Operating Officer and Chief Business Officer |
| Sarah Nemec | Senior Vice President of Finance and Principal Accounting Officer |
| Wesley Burwell | Vice President and Head of Human Resources |
| Dr. Nathan Ihle Ph.D. | Senior Vice President of Pharmaceutical Operations |
| Dr. Michael N. Alonso Ph.D. | Senior Vice President of Research |
| Justin Kenkel | Senior Principal Scientist |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 6, 2025 | 8-K | Current Report |
| Jun 4, 2025 | 8-K | Current Report |
| May 28, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 12, 2025 | 10-Q | Quarterly Report |
| May 12, 2025 | 8-K | Current Report |
| Apr 25, 2025 | ARS | Filing |
| Apr 25, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 16, 2025 | 8-K | Current Report |
| Apr 16, 2025 | PRE 14A | Other preliminary proxy statements |